STK11 and non-small cell lung carcinoma: For instance, it can predict whether a tumor will respond to immunotherapy, even if all that is known about a particular NSCLC patient is that they have TP53 and STK11 variants; the estimated response probability is 0.163, indicating that this patient would not benefit substantially from ICIs (Fig. 5).